Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2010

View Archived Issues

CAT promoter polymorphism is linked to risk of vitiligo in Chinese individuals

Dutch scientists patent new modulators of glycoprotein hormone LH receptor

FDA sets PDUFA date for Endo Pharma's new formulation of long-acting oxymorphone hydrochloride

Curemark receives grant for development of CM-AT

Phase II data show benefit of pentoxifylline in nonalcoholic steatohepatitis

PLX-5622 reduces disease activity in a model of rheumatoid arthritis

In vivo data support potential of galantamine for treatment of obesity and related complications

Long-term Arikace therapy is well tolerated in patients with CF and P. aeruginosa infection

ECLIPSE trial compares Epanova with Lovaza

Nuvo Research presents topline phase II data on WF-10 in allergic rhinitis

Enrollment completed in Nabi Biopharma' second phase III NicVAX trial

FDA clears phase II trial of MultiStem in ulcerative colitis

TransTech Pharma and High Point Pharmaceuticals receive grants for development projects

Novel cannabinoid CB2 receptor ligands claimed by sanofi-aventis

Shire finalizes acquisition of Movetis

Infinity Pharma patents new fatty-acid amide hydrolase 1 inhibitors

Actelion Pharmaceuticals discloses novel antibacterial agents

Kyorin Pharma claims new muscarinic M3 receptor antagonists

Xoma receives grants to advance ongoing MAb development projects

MAP Pharmaceuticals reports results from Levadex QT trial

BioInvent receives FDA clearance for phase II trial of BI-204

Enanta Pharma discloses new HCV NS5 inhibitors

Apogee Biotech to begin phase I ABC-294640 development in several types of cancer

NeoPharm and Insys Therapeutics complete merger

Patient screening complete for phase III rhGAD65 trial in type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...